These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21098981)

  • 1. The reduction of baseline serotonin 2A receptors in mild cognitive impairment is stable at two-year follow-up.
    Marner L; Knudsen GM; Madsen K; Holm S; Baaré W; Hasselbalch SG
    J Alzheimers Dis; 2011; 23(3):453-9. PubMed ID: 21098981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
    Drzezga A; Lautenschlager N; Siebner H; Riemenschneider M; Willoch F; Minoshima S; Schwaiger M; Kurz A
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1104-13. PubMed ID: 12764551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study.
    Marner L; Frokjaer VG; Kalbitzer J; Lehel S; Madsen K; Baaré WF; Knudsen GM; Hasselbalch SG
    Neurobiol Aging; 2012 Mar; 33(3):479-87. PubMed ID: 20510480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment.
    Hasselbalch SG; Madsen K; Svarer C; Pinborg LH; Holm S; Paulson OB; Waldemar G; Knudsen GM
    Neurobiol Aging; 2008 Dec; 29(12):1830-8. PubMed ID: 17544547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders.
    Meltzer CC; Price JC; Mathis CA; Greer PJ; Cantwell MN; Houck PR; Mulsant BH; Ben-Eliezer D; Lopresti B; DeKosky ST; Reynolds CF
    Am J Psychiatry; 1999 Dec; 156(12):1871-8. PubMed ID: 10588399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.
    Hunt A; Schönknecht P; Henze M; Seidl U; Haberkorn U; Schröder J
    Psychiatry Res; 2007 Jul; 155(2):147-54. PubMed ID: 17524628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study.
    Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J
    Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease.
    Lai MK; Tsang SW; Alder JT; Keene J; Hope T; Esiri MM; Francis PT; Chen CP
    Psychopharmacology (Berl); 2005 May; 179(3):673-7. PubMed ID: 15551121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT.
    Hirao K; Ohnishi T; Hirata Y; Yamashita F; Mori T; Moriguchi Y; Matsuda H; Nemoto K; Imabayashi E; Yamada M; Iwamoto T; Arima K; Asada T
    Neuroimage; 2005 Dec; 28(4):1014-21. PubMed ID: 16129627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
    Waragai M; Okamura N; Furukawa K; Tashiro M; Furumoto S; Funaki Y; Kato M; Iwata R; Yanai K; Kudo Y; Arai H
    J Neurol Sci; 2009 Oct; 285(1-2):100-8. PubMed ID: 19552926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.
    Sabbagh MN; Shah F; Reid RT; Sue L; Connor DJ; Peterson LK; Beach TG
    Arch Neurol; 2006 Dec; 63(12):1771-6. PubMed ID: 17172618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evidence of Alzheimer changes in progressive mild cognitive impairment: a qualitative and quantitative SPECT study.
    Ishiwata A; Sakayori O; Minoshima S; Mizumura S; Kitamura S; Katayama Y
    Acta Neurol Scand; 2006 Aug; 114(2):91-6. PubMed ID: 16867030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cortical thickness analysis to detect progressive mild cognitive impairment: a reference to Alzheimer's disease.
    Julkunen V; Niskanen E; Muehlboeck S; Pihlajamäki M; Könönen M; Hallikainen M; Kivipelto M; Tervo S; Vanninen R; Evans A; Soininen H
    Dement Geriatr Cogn Disord; 2009; 28(5):404-12. PubMed ID: 19907176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.
    Ito K; Shimano Y; Imabayashi E; Nakata Y; Omachi Y; Sato N; Arima K; Matsuda H
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1079-86. PubMed ID: 24687634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment.
    Habert MO; Horn JF; Sarazin M; Lotterie JA; Puel M; Onen F; Zanca M; Portet F; Touchon J; Verny M; Mahieux F; Giron A; Fertil B; Dubois B
    Neurobiol Aging; 2011 Jan; 32(1):15-23. PubMed ID: 19250707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment].
    Cao Q; Jiang K; Liu Y; Zhang M; Xiao S; Zuo C; Huang H
    Zhonghua Yi Xue Za Zhi; 2002 Dec; 82(23):1613-6. PubMed ID: 12667368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.
    Koivunen J; Karrasch M; Scheinin NM; Aalto S; Vahlberg T; Någren K; Helin S; Viitanen M; Rinne JO
    Dement Geriatr Cogn Disord; 2012; 34(1):31-7. PubMed ID: 22868352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-quantitative analysis of perfusion of Brodmann areas in the differential diagnosis of cognitive impairment in Alzheimer's disease, fronto-temporal dementia and mild cognitive impairment.
    Tranfaglia C; Palumbo B; Siepi D; Sinzinger H; Parnetti L
    Hell J Nucl Med; 2009; 12(2):110-4. PubMed ID: 19675861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.